WHO Identifies Potential Ebola Vaccines for Clinical Trials Amid Outbreak
The WHO said it is working closely with Congo and Uganda ‘to facilitate the implementation of research evaluation’ of the products.
WHO Identifies Potential Ebola Vaccines for Clinical Trials Amid Outbreak Experts convened by the World Health Organization have identified vaccine candidates and treatments for the Bundibugyo strain of Ebola. Among these, a single-dose vaccine called rVSV Bundibugyo is considered the most promising, though it requires an additional seven to nine months before clinical trials can commence. This development comes in response to the ongoing outbreak in Congo.
- WHO experts have identified potential vaccine candidates and treatments for the Bundibugyo strain of Ebola.
- A single-dose vaccine, rVSV Bundibugyo, developed by the International AIDS Vaccine Initiative, is considered the most promising candidate.
- This promising vaccine is estimated to be ready for clinical trials in seven to nine months.
- The WHO is responding to the Ebola outbreak in Congo by assessing these potential medical interventions.
Write a comment